A recent article published in Science presents research on the precision management of fibrotic lung diseases, addressing a significant challenge in the field due to diverse clinical trajectories and the absence of reliable biomarkers for risk stratification and therapeutic monitoring.
The study highlights CMKLR1 as a novel imaging biomarker for the lung inflammation-fibrosis axis. Researchers validated its accuracy by analyzing single-cell RNA sequencing datasets, revealing CMKLR1 expression as a transient signature in monocyte-derived macrophages (MDM?) particularly enriched in patients with idiopathic pulmonary fibrosis (IPF).
In a murine model of bleomycin-induced lung fibrosis, MDM? were identified as the primary drivers of CMKLR1-targeting peptide uptake. This discovery was further substantiated using CMKLR1-targeted positron emission tomography (PET), which enabled precise quantification and spatial mapping of inflamed lung regions infiltrated by CMKLR1-expressing macrophages. The PET imaging emerged as a robust predictor of subsequent lung fibrosis.
Additionally, high CMKLR1 expression in bronchoalveolar lavage cells identified an inflammatory endotype of IPF associated with poor survival outcomes. This indicates the potential of CMKLR1 as a critical imaging biomarker for endotyping and risk stratification in fibrotic lung diseases, paving the way for improved therapeutic strategies and patient management.
This research marks a significant advance in the quest for precision medicine in treating fibrotic lung diseases, offering hope for better diagnostic and prognostic tools in the fight against these challenging conditions.